Advanced Lung Cancer
Conditions
Brief summary
This is a multicenter, open-label Phase II clinical study, with the main objective being to evaluate the investigator-assessed objective response rate of JS212 in combination therapy for advanced lung cancer. The aim is to explore the safety, tolerability, and preliminary efficacy of JS212 combined with JS207, Toripalimab, JS213 combined or not combined with chemotherapy.
Detailed description
Part One: The plan involves including patients with previously failed standard treatments in advanced NSCLC and ES-SCLC. It consists of two phases: safety introduction and clinical expansion, covering cohorts 1 to 3. The safety introduction phase will explore the safety of the following combined regimens in the target population: Queue 1: JS212 + JS207 Queue 2: JS212 + Toripalimab Queue 3: JS212 + JS213 Part Two: It is planned to include lung cancer patients who have not received any systemic anti-tumor treatment for advanced NSCLC and ES-SCLC in the past. If the SMC decides to further combine chemotherapy, the safety introduction phase should also include to ensure the safety of the subjects.
Interventions
Administered by intravenous infusion on Day 1 of each 21-day cycle.
Administered by intravenous infusion on Day 1 of each 21-day cycle.
DRUGToripalimab
Administered by intravenous infusion on Day 1 of each 21-day cycle.
Administered by intravenous infusion on Day 1 of each 21-day cycle.
Sponsors
Shanghai Junshi Bioscience Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The age between 18 and 75 years old, and any gender. 2. Local advanced, metastatic or recurrent NSCLC. 3. ES-SCLC. 4. According to the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), there must be at least one measurable lesion. 5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. 6. Expected survival period of ≥ 12 weeks. 7. The functions of important organs meet the requirements. 8. Female participants with reproductive capacity (WOCBP) who have sexual life with an unsterilized male partner and who have signed the informed consent must have a negative serum pregnancy test result within 7 days before the first administration, and must agree to take effective contraceptive measures from the time of signing the ICF until 7 months after the last administration of the study. 9. Unsterilized male participants who have sexual life with a fertile female partner must agree to use the effective contraceptive measures after signing the ICF until 4 months after the last administration of the study. During this period, sperm donation is prohibited. 10. The participants voluntarily participate in this study and sign the informed consent.
Exclusion criteria
1\. Accompanying the following disease states: 1. Tumor histological or cytological pathological confirmation of combined large cell neuroendocrine carcinoma or sarcomatoid lesion, or NSCLC with small cell lung cancer component; 2. NSCLC patients with positive driver mutations; 3. Patients with known meningeal metastasis; 4. Patients with symptomatic brain metastases; 5. Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites; 6. Unatable spinal cord compression; 2\. Participants in Cohort 1 and Cohort 4 need to exclude any of the following conditions: 1. Within one month before the first use of the study drug, any clinically significant hemoptysis or tumor bleeding; 2. High bleeding risk; tumor invading important organs, high risks of perforation, esophageal-tracheal fistula, massive hemoptysis, etc.; 3. Obvious bleeding tendency or severe coagulation dysfunction history, etc; 4. Recent gastrointestinal perforation, gastrointestinal obstruction, trachea-esophageal fistula, abdominal fistula or intra-abdominal abscess, or currently having high-risk factors for hollow organ perforation/ fistula formation, or active inflammatory bowel disease, etc; 5. Presence of severe, non-healed or open wounds, active ulcers or untreated fractures; 6. Have poorly controlled hypertension; 7. Have used antiplatelet drugs or anticoagulant therapy within 14 days; 8. Have experienced a drug-related adverse event that led to permanent discontinuation of the medication during previous Bevacizumab and similar agent treatments; 3\. Have received any of the following treatments: 1. Immune-mediated treatments (only for part Two); 2. Have received any investigational drug within 4 weeks or 5 half-lives before the first use of the study drug; 3. Have been enrolled in another clinical study; 4. Have undergone major surgery within 4 weeks; 5. Have received local small-scale radiotherapy within 14 days; 4.Have not recovered to ≤ CTCAE grade 1 toxicity or the level specified in the inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | up to 6 years | Objective response rate(ORR), assessed by BICR (RECIST v1.1) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | up to 6 years | Progression-free survival (PFS), assessed by investigators (RECIST v1.1) |
| DoR | up to 6 years | Duration of response (DoR), assessed by BICR and investigators |
| DCR | up to 6 years | Disease control rate (DCR), assessed by BICR and investigators |
| OS | up to 6 years | overall survival (OS) |
| Safety (AE) | up to 6 years | Incidence and severity of adverse events (AEs) |
| Number of Participants With Abnormal Laboratory Values or clinical findings | up to 6 years | Abnormal laboratory or clinical findings |
| dose-limiting toxicity（DLT） | up to 6 years | Incidence and severity of dose-limiting toxicity（DLT） |
| blood concentrations of JS212, JS207,toriplimab, or JS213 | up to 2 years | Evaluation of blood concentrations of JS212, JS207,toriplimab, or JS213 |
| ADA incidence | up to 4 years | Incidence and titers of anti-drug antibodies (ADA) for JS212,JS207,toriplimab, or JS213; neutralizing antibodies (NAb) if applicable. |
Countries
China
Contacts
CONTACTWeilong Ni, Master
Outcome results
None listed